Browsing Tag
obesity treatment
41 posts
Can Camurus’ once-monthly semaglutide depot reshape the future of obesity and diabetes treatment?
Camurus reports positive Phase 1b results for CAM2056, a monthly semaglutide depot, showing 9.3% weight loss and strong A1c reduction. Read the full data.
Novo Nordisk taps Emcure Pharmaceuticals to launch Poviztra in India as second brand of Wegovy
Novo Nordisk partners with Emcure Pharmaceuticals to launch Poviztra, a second brand of Wegovy, in India. Discover how this could reshape obesity treatment access.
Rhythm Pharmaceuticals’ IMCIVREE hits regulatory speed bump as FDA extends decision timeline into 2026
Find out how Rhythm Pharmaceuticals’ IMCIVREE FDA review delay could shape the rare obesity treatment market in 2026.
Viking Therapeutics’ GLP-1/GIP dual agonist VK2735 impresses at ObesityWeek 2025 with sustained weight-loss efficacy
Find out how Viking Therapeutics’ VK2735 is redefining obesity treatment with sustained clinical results — see what this breakthrough means for patients and investors today!
From GLP-1 to FGF21: How Novo Nordisk’s Akero Therapeutics deal signals a new era in metabolic drug dominance
Novo Nordisk’s $5.2 B Akero deal adds the FGF21 drug efruxifermin to its MASH portfolio. See how it expands the company’s metabolic dominance.
Sen-Jam’s SJP-002C gets FDA-ready CMC milestone as investors eye late-stage trial momentum
Sen-Jam finalizes NDA-ready CMC deliverables for SJP-002C with KVK Tech and expands investor engagement, positioning for Phase 2b/3 trials.
Wegovy cuts cardiovascular event risk by over half vs tirzepatide—real-world data raises Novo Nordisk lead
Discover how Novo Nordisk’s Wegovy reduced heart attack, stroke, and death risk by 57% vs tirzepatide in real-world study. Read the STEER findings now.
Ascletis Pharma completes dosing in U.S. ASC47-semaglutide study for obesity treatment
Ascletis Pharma completes dosing in its ASC47-semaglutide obesity trial. Find out why Q4 2025 data could be a game changer for muscle-preserving weight loss.
How oral obesity drugs are changing treatment access: A look at semaglutide, amycretin, and orforglipron
Oral GLP-1 drugs like semaglutide, amycretin, and orforglipron are redefining obesity care. Explore trial data, payer impact, and what’s ahead for access and scale.
Can dual agonist drugs like amycretin and tirzepatide replace bariatric surgery by 2030?
Can new obesity drugs like amycretin and tirzepatide replace bariatric surgery by 2030? Discover what clinical data and cost trends reveal about the future.